Oncology R&D driving strategic transformation
The growing complexity of oncology drug development is driving biopharmas to transform their portfolios and partnerships and rethink their approach to market leadership.
Oncology R&D driving strategic transformation
The growing complexity of oncology drug development is driving biopharmas to transform their portfolios and partnerships and rethink their approach to market leadership.
Streamlining drug development – at scale
Gain insight into a uniquely structured company that aims to reduce the time, cost and risk of delivering drugs to market.
Japan: leading the way in regenerative medicine
Japan's large and growing elderly population, plus its long-term vision for health care solutions, has led to regenerative medicine becoming key to their government strategy.
Putting China's capital to work in the West
With new sources emerging rapidly, China has abundant capital for outbound investment in innovative assets and technologies across numerous sectors including health and life sciences.
Embedding digital into pharma's DNA
Pharmas have increased their interest in digital capabilities, especially for clinical trials and gathering real world evidence, as well as for consumer applications.
Augmenting R&D with artificial intelligence
How can artificial intelligence better analyse research information and outcomes data to improve drug R&D? See our interview with BenevolentBIO CEO Jackie Hunter.
Value-based healthcare and Value Labs
Learn in this In Vivo article how a proposed new approach to value-based contracts could help drive the shift to value-based reimbursements and drug pricing.
Life sciences dealmaking expected to continue
Our Global Capital Confidence Barometer shows that policy reform and portfolio rationalisation have heightened dealmaking activity across the life sciences spectrum.

Life Sciences

The need for alignment to achieve health outcomes for all

As populations age and chronic diseases become commonplace, health care will take an ever larger share of GDP. Scientific progress, augmented intelligence and a more empowered patient are driving changes in the delivery of health care to a personalized experience that demands health outcomes as the core metric. This is causing a power shift among traditional stakeholder groups, with new entrants (often not driven by profit) disrupting incumbents.

Innovation, productivity and access to patients remain the industry’s biggest challenges. These trends challenge the capital strategy of every link in the life sciences value chain, from R&D and product supply to product launch and patient-centric operating models.

Our Global Life Sciences Sector brings together a worldwide network of 11,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. We can help you navigate your way forward and achieve sustainable success in the new health-outcomes-driven ecosystem.

EY's top five Knowledge Development Box (KDB) considerations for Life Science companies

The KDB is aimed at incentivising innovative R&D activities by taxing qualifying profits from patented inventions and copyrighted software at 6.25%. This following infographic showcases the 5 key areas Life Sciences companies should consider in accessing the benefits of KDB.

For more details, read EY’s KDB for Life Sciences report.

EY's top five Knowledge Development Box (KDB) considerations for Life Science companies

Contact us

EY - Aidan Meagher

Aidan Meagher
Partner
Head of Life Sciences
Tax Services
+353 (1) 221 1139
linkedIn Aidan Meagher Aidan Meagher

EY - Graham Reid

Graham Reid
Partner
Corporate Finance
Head of Transaction Advisory Services
+353 1 221 1449
linkedIn Graham Reid Graham Reid

EY - Feargal De Freine

Feargal De Freine
Assurance Partner
+353 1 221 1636
linkedIn Feargal De Freine Feargal De Freine

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

Vital Signs

EY are proud platinum sponsors of the Innovation in MedTech Summit, Dublin, 25 – 27 April 2017, The Shelbourne Hotel, Dublin. This annual conference is the leading MedTech investment forum in Europe.